Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF) (GWAS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01088217 |
Recruitment Status :
Recruiting
First Posted : March 17, 2010
Last Update Posted : September 14, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Idiopathic Pulmonary Fibrosis Familial Pulmonary Fibrosis Idiopathic Interstitial Pneumonia Familial Interstitial Pneumonia |
Study Type : | Observational |
Estimated Enrollment : | 8000 participants |
Observational Model: | Family-Based |
Time Perspective: | Cross-Sectional |
Official Title: | Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF) |
Study Start Date : | July 2008 |
Estimated Primary Completion Date : | June 2025 |
Estimated Study Completion Date : | June 2025 |
- Identify a group of genetic loci that play a role in the development of familial interstitial pneumonia and idiopathic interstitial pneumonia. [ Time Frame: 10 years ]The purpose of this study is to investigate inherited genetic factors that play a role in the development of pulmonary fibrosis and to identify a group of genetic loci/genes that predispose individuals to develop IIP. We will achieve this goal by employing various methods of genetic technology for gene discovery.
- Develop biomarkers using proteomic and genomic approaches that will facilitate establishing the diagnosis and prognosis of both familial and sporadic forms of idiopathic interstitial pneumonia (IIP). [ Time Frame: 10 years ]A peripheral blood biomarker or biological signature (gene or protein expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve the accuracy of diagnosis of IIP and diagnose individuals at an earlier, more treatable, stage of their disease. A peripheral blood biomarker for the diagnosis of IIPs and other interstitial lung diseases (ILDs) will potentially decrease the need for invasive surgical lung biopsy, and thereby avoid the additional cost, morbidity, and mortality associated with surgical lung biopsy.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Two or more family members with a clinical diagnosis of Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic Interstitial Pneumonia (IIP)
- Additional family members may be eligible to participate if two family members are suspected of or diagnosed as having Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic Interstitial Pneumonia (IIP)
Exclusion Criteria:
- Individuals whose pulmonary fibrosis is due to a known cause rather than idiopathic
- Individuals whose pulmonary fibrosis is due to a broader genetic syndrome
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01088217
Contact: Julie Powers, MHS | 303-724-6539 | julia.powers@ucdenver.edu | |
Contact: Janet Talbert, MS, CGC | 1-800-423-8891 ext 1022 | talbertj@njhealth.org |
United States, Colorado | |
University of Colorado Denver | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Julie Powers, MHS 303-724-6539 julia.powers@ucdenver.edu | |
Contact: Janet Talbert, MS, CGC 1-800-423-8891 ext 1022 talbertj@njhealth.org | |
Principal Investigator: David A. Schwartz, MD | |
Sub-Investigator: Marvin I Schwarz, MD | |
Sub-Investigator: Ivana Yang, PhD | |
Sub-Investigator: Tasha E Fingerlin, PhD | |
Sub-Investigator: Rebecca Keith, MD | |
Sub-Investigator: Carlyne Cool, MD | |
Sub-Investigator: Anna Peljto, DrPh | |
National Jewish Health and University of Colorado Denver | Recruiting |
Denver, Colorado, United States, 80206 | |
Contact: Janet Talbert, MS, CGC 800-423-8891 ext 1022 talbertj@njhealth.org | |
Contact: Julie Powers, MHS 303-724-6539 julia.powers@ucdenver.edu | |
Principal Investigator: David A. Schwartz, MD | |
Sub-Investigator: Kevin K. Brown, MD | |
Sub-Investigator: Gregory P. Cosgrove, MD | |
Sub-Investigator: Marvin I. Schwarz, MD | |
Sub-Investigator: Tasha Fingerlin, PhD | |
Sub-Investigator: Steve Groshong, MD, PhD | |
Sub-Investigator: David Lynch, MD | |
Sub-Investigator: James Crapo, MD | |
United States, Tennessee | |
Vanderbilt University | Recruiting |
Nashville, Tennessee, United States, 37232 | |
Contact: Cheryl Markin, MT 888-898-1550 cheryl.markin@vanderbilt.edu | |
Principal Investigator: James E. Loyd, MD | |
Iceland | |
Landspitali University Hospital | Recruiting |
Reykjavik, Iceland | |
Principal Investigator: Gunnar Gudmundsson, MD |
Principal Investigator: | David A. Schwartz, MD | University of Colorado Denver; National Jewish Health |
Responsible Party: | National Jewish Health |
ClinicalTrials.gov Identifier: | NCT01088217 |
Other Study ID Numbers: |
2R01HL097163 ( U.S. NIH Grant/Contract ) |
First Posted: | March 17, 2010 Key Record Dates |
Last Update Posted: | September 14, 2020 |
Last Verified: | September 2020 |
Idiopathic Pulmonary Fibrosis Familial Pulmonary Fibrosis Idiopathic Interstitial Pneumonia Familial Interstitial Pneumonia Pulmonary Fibrosis |
Pneumonia Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Lung Diseases, Interstitial Idiopathic Interstitial Pneumonias Hamman-Rich Syndrome |
Fibrosis Pathologic Processes Respiratory Tract Infections Infections Lung Diseases Respiratory Tract Diseases |